Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
Login Archives Your Team About Us FAQ
[mmpazkzone name="azk58712-mobile-nav" network="9794" site="307044" id="222451" type="5"]
  • Subscribe
Enter stock ticker or keyword
×
[mmpazkzone name="azk58712-mobile-sticky" network="9794" site="307044" id="222451" type="5"]
Join 100,000+ Like-Minded Investors Today
Twitter
Tags: Stocks
Stocks: CO

This Lifesaving Small Cap Is Set to Triple in Value

By Stephen Mack, Associate Editor, Money Morning • October 10, 2019

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

There's a revolution going on in life sciences right now.

We're talking about an emerging treatment that can already cure 75 diseases, including red blood cell disorders, sickle cell anemia, immunodeficiency disorders, and malignant tumors.

And it might not be long before you can add diabetes, liver disease, and nerve deficiencies to the list.

With global healthcare expenditures set to exceed $10 trillion in 2022, according to Deloitte, the few companies that can provide this lifesaving treatment are going to reap major windfalls.

In fact, one small-cap stock we're bringing you today is due to triple in value, based on multiple valuation figures.

This company controls more than 40% of the existing Chinese market for this groundbreaking treatment, with a potential market of 2 million clients per year.

Even better, it just got a top score from our Money Morning Stock VQScore™ system.

All that makes this stock to buy the top choice to capitalize on this lifesaving trend...

750,000-Plus Clients Trust This Firm to Save Their Lives - and That's Just the Beginning

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]You've probably already heard about the medical uses of stem cells. But you might not know about the easiest, most efficient way to get access to them: through "cord blood" taken from a newborn's umbilical cord.

Global Cord Blood Corp. (NYSE: CO) is a leader in the storage of cord blood. It holds three of the seven licenses that have been given out in China for this purpose, covering Beijing, Guangdong, and Zhejiang.

About 2 million babies are born each year in those areas. Expectant mothers concerned about the long-term health of their children can sign up to have the cord blood stored for an initial contract period of 18 years.


Click here to see all of our top-rated stocks, and you'll automatically get free updates on our top stocks, based on our proprietary rating system, the Money Morning Stock VQScore™.

If those children grow up to have one of the 75 diseases currently treatable by stem cell implants, not just any stem cells will do. If the cells aren't an "HLA" match (that stands for "human leukocyte antigens"), the body won't accept them.

Siblings have about a 25% chance of being a match. For unrelated humans, the chance of a match could be as low as one in 10,000.

So the painless procedure of storing a newborn child's umbilical cord blood is a tremendous insurance policy against the many diseases that can be treated with stem cells.

Plus, the untapped potential of stem cell treatment means that by the time the child grows up, there could be dozens more diseases that are treatable with matching cord blood.

GCBC opened its first storage bank in 2003, with two more added in 2007 and 2011. Because this is a relatively new venture, the bulk of revenue currently comes from the initial processing fees from new clients.

But while that revenue is growing about 9% per year, revenue from storage fees is climbing almost twice as fast.

The reason, of course, is that as new clients sign up, they pay storage fees for decades.

GCBC is up to more than 750,000 subscribers as of June 2019. With growing awareness of the benefits of cord blood storage, and more than 350 collaborating hospitals in China, this is a company with tremendous potential for growth.

And right now is the perfect time to buy...

Now Is the Time to Buy CO

In addition to revenue growing by double-digit percentages every year, Global Cord Blood Corp. has put up impressive earnings growth in recent quarters.

Earnings per share last quarter beat the year-before quarter by 33%. The quarter before that, it was 175%. And with a subscriber base that has grown more than 50% in the last three years, you can expect substantial earnings growth for years to come.

And yet, CO's stock price - currently under $5 per share - has not kept up with the fundamentals.

The company's price/earnings ratio for the last 12 months comes in at just 11.46, compared to an industry average of 35.22. That means CO's share price would have to multiply threefold to be in line with its peers.

That's not an outlier, either. CO's price-to-book ratio also comes in at just a third of the industry average.

No wonder this stock earned a top score.

Between the incredible growth prospects of cord blood stem cells and the steep discount in CO's stock price, this pick is a no-brainer for smart investors.

Follow Money Morning on Facebook and Twitter.

Stephen MackStephen Mack

About the Author

Browse Stephen's articles |

Stephen Mack has been writing about economics and finance since 2011. He contributed material for the best-selling books Aftershock and The Aftershock Investor. He lives in Baltimore, Maryland.

… Read full bio

ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us How Money Morning Works FAQs Contact Us Search Article Archive Your Team Text Messaging Terms of Use
TOPICS
AI Investing Best Stocks to Buy Stock Forecasts Stocks to Sell Now Technology Stocks Best REITs to Buy Now IPO Stocks Penny Stocks Dividend Stocks Cryptocurrencies How to Trade Options Best Trades to Make Now Options Trading Strategies Weekly Trade Recommendations Income Investing Guide Retirement Articles Special Investing Reports Meet Our Experts
PREMIUM SERVICES
Money Map Press Home Fast Fortune Club Microcurrency Trader Rocket Wealth Initiative Quantum Data Profits Darknet Alpha Accelerators Brutus Alerts Resource Traders Alliance Rob Roy Trader Long-Term Equity Profits

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information